Rezolute (RZLT) Total Non-Current Liabilities (2011 - 2020)
Rezolute (RZLT) reported Total Non-Current Liabilities of $3.6 million for Q2 2020, up 69.73% on a YoY basis from $2.1 million in Q3 2019, and down 17.49% sequentially from $4.4 million in Q1 2020.
Rezolute (RZLT) Total Non-Current Liabilities (2011 - 2020) Analysis & Trends
Rezolute (RZLT) has 8 years of Total Non-Current Liabilities data on file, last reported at $3.6 million in Q2 2020.
- For the quarter ending Q2 2020, Total Non-Current Liabilities rose 69.73% year-over-year to $3.6 million; the trailing twelve-month figure through Jun 2020 stood at $3.6 million (up 69.73% YoY), and the FY2020 full-year result was $3.6 million, up 69.73% from the prior year.
- Total Non-Current Liabilities declined to $3.6 million in Q2 2020, from $4.4 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $10.8 million in Q1 2019 to a low of $173270.0 in Q3 2018.
- A 5-year average of $2.6 million and a median of $383925.5 in 2016 frame the typical range for Total Non-Current Liabilities.
- Across the five-year window, Total Non-Current Liabilities surged 4443.42% in 2019 and sank 59.55% in 2020, its largest moves.
- Tracing RZLT's Total Non-Current Liabilities over 5 years: stood at $335588.0 in 2016, then dropped by 19.92% to $268732.0 in 2017, then surged by 3711.74% to $10.2 million in 2018, then sank by 43.09% to $5.8 million in 2019, then tumbled by 38.24% to $3.6 million in 2020.
- Business Quant data shows RZLT's Total Non-Current Liabilities at $3.6 million in Q2 2020, $4.4 million in Q1 2020, and $5.8 million in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | Rezolute | 31,153.77 | 31,153.77 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2020 | 3.60 Mn |
| Mar 31, 2020 | 4.36 Mn |
| Dec 31, 2019 | 5.83 Mn |
| Sep 30, 2019 | 5.87 Mn |
| Jun 30, 2019 | 2.12 Mn |
| Mar 31, 2019 | 10.79 Mn |
| Dec 31, 2018 | 10.24 Mn |
| Sep 30, 2018 | 173,270.00 |
| Jun 30, 2018 | 215,623.00 |
| Mar 31, 2018 | 237,404.00 |
| Dec 31, 2017 | 268,732.00 |
| Sep 30, 2017 | 299,176.00 |
| Jun 30, 2017 | 329,621.00 |
| Mar 31, 2017 | 314,655.00 |
| Dec 31, 2016 | 335,588.00 |
| Sep 30, 2016 | 367,813.00 |
| Jun 30, 2016 | 400,038.00 |
| Mar 31, 2016 | 431,341.00 |
| Dec 31, 2015 | 460,794.00 |
| Sep 30, 2015 | 453,586.00 |